Compare MSA & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSA | LEGN |
|---|---|---|
| Founded | 1914 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.9B |
| IPO Year | N/A | 2020 |
| Metric | MSA | LEGN |
|---|---|---|
| Price | $184.23 | $22.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | ★ $185.25 | $69.33 |
| AVG Volume (30 Days) | 236.2K | ★ 2.1M |
| Earning Date | 02-11-2026 | 03-10-2026 |
| Dividend Yield | ★ 1.15% | N/A |
| EPS Growth | ★ 3.07 | N/A |
| EPS | ★ 7.10 | N/A |
| Revenue | ★ $1,863,597,000.00 | $909,045,000.00 |
| Revenue This Year | $4.58 | $68.20 |
| Revenue Next Year | $5.61 | $47.77 |
| P/E Ratio | $26.00 | ★ N/A |
| Revenue Growth | 3.31 | ★ 74.75 |
| 52 Week Low | $127.86 | $20.21 |
| 52 Week High | $185.02 | $45.30 |
| Indicator | MSA | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 79.76 | 42.47 |
| Support Level | $166.57 | $20.21 |
| Resistance Level | $170.08 | $24.12 |
| Average True Range (ATR) | 3.82 | 1.05 |
| MACD | 1.93 | 0.30 |
| Stochastic Oscillator | 98.79 | 47.57 |
MSA Safety Inc makes safety products that are used to protect workers in the oil and gas and mining industries. The products include breathing apparatuses, fall protection, portable gas detection systems, industrial head protection, fire and rescue helmets, and fixed gas and flame detection systems. End markets include the fire service, contractor, industrial, mining, oil and gas, and utilities industries. The company's reportable geographic segments are Northern North America; Latin America; Europe, Middle East & Africa; and Asia Pacific. The company's operating segments have been aggregated into three reportable segments: Americas, International, and Corporate. Geographically the company generates the majority of its revenue from the United States.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.